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Abstract
Background: Recent reports have suggested that Common Variable Immunodeficieny (CVID) can
present as an autosomal dominant trait dependent on the inheritance of a set of uncommon
mutations/alleles of TACI (transmembrane activator and calcium-modulator and cyclophilin ligand
interactor) involving exons 3 or 4. Penetrance, however, appears to be incomplete. Among our
clinic population, the greatest genetic linkage for CVID is to the major histocompatibility complex
(MHC) on chromosome 6. The majority of our patients have inherited HLA *DQ2, *DR7,
*DR3(17), *B8, and/or *B44. Of these, HLA*B44 was present in almost half of the patients and was
thus the most common susceptibility allele. HLA *B44 was also found to be over-represented
among patients who presented to our clinic with adult-onset recurrent sinopulmonary infections
(RESPI) and normal serum immunoglobulin levels, a cohort that included first and second degree
relatives of patients with CVID. One of the two original reports of the association between TACI
and CVID also reported Human Leukocyte Antigen (HLA) haplotypes. Of 13 affected subjects, nine
had inherited HLA *B8 and six had inherited HLA B44. This raised the possibility that TACI
mutations might synergize with MHC class I alleles to enhance susceptibility to humoral immune
deficiency.
Methods: We identified 63 CVID patients irrespective of HLA status and 13 RESPI patients who
had inherited HLA*B44. To evaluate for mutations in the gene for TACI, we PCR amplified and
sequenced TACI exons 3 and 4 from these patients.
Results: Of the 76 patients, eleven proved heterozygous for a previously reported, silent T->G
polymorphism [rs35062843] at proline 97 in exon 3. However, none of the 13 RESPI patients and
only one of the 63 CVID patients inherited a TACI allele previously associated with CVID. This
patient was heterozygous for the TACI A181E allele (exon 4). She did not carry *DQ2, *DR7,
*DR3(17), *B8, or *B44.
Conclusion: These findings suggest that TACI mutations are unlikely to play a critical role in
creating susceptibility to CVID among patients with previously recognized MHC class I and class II
susceptibility alleles.
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Background
In the United States, CVID is the most common primary
immunodeficiency under the care of the clinical immu-
nologist. CVID is a clinical diagnosis given to patients
with unexplained pan-hypogammaglobulinemia in the
presence of normal or near-normal B cell numbers. It has
been called agammaglobulinemia with B cells to distin-
guish it from Bruton's agammaglobulinemia [1]. The
most common clinical presentation is a history of recur-
rent pyogenic sinopulmonary infections [2,3]. Among
Americans of European descent, it affects approximately 1
in 25,000 [4,5]. The frequency among Americans of Afri-
can descent is twenty-fold lower [6]. These ethnic associa-
tions, coupled with the results of familial studies, have
suggested that CVID has a strong genetic component
[7,8]. However, identification of the causative genes has
been difficult. It remains unclear whether the disease
reflects a single Mendelian trait with incomplete pene-
trance, or whether it is the result of a combination of
genetic lesions and environmental influences.
In our clinic in the Southeastern United States, the major-
ity of patients with CVID have inherited part or all of two
extended MHC haplotypes: HLA*DQ2,*DR7,*B44 or
*DQ2,*DR3(17),*B8 [6]. These haplotypes are also com-
mon in patients with selective IgA deficiency (IgAD) [8-
10]. In our population, hypogammaglobulinemia
appears more closely linked to the class I locus than class
II, with almost half of our patients inheriting HLA B44 [6].
In 2005, Johnston et al studied a series of patients who
had presented to our clinic with a history of sinopulmo-
nary infections (RESPI) similar in frequency and severity
to that observed in CVID, but with normal serum levels of
IgM and IgA and with IgG serum levels of 600 mg/dl or
greater [11]. The distribution of MHC class I alleles in this
RESPI population proved similar to CVID, with almost
half of the patients inheriting HLA-B44. This led to the
suggestion that RESPI might reflect a more moderate form
of the same immune dysfunction that underlies the com-
bination of recurrent infections and panhypogammaglob-
ulinemia in CVID.
In the continuing search for genes that might contribute
to the CVID phenotype, a number of investigators have
focused on the study of candidates involved in either B
cell proliferation or survival. In 2005, Salzer et al [12] and
Castigli et al [13] reported an association between muta-
tions in exon 3 or 4 in TACI and CVID. The complexity of
the genetics of CVID and the role of TACI mutations is
underscored by the recent report of discordance between
the inheritance C104R mutation and CVID in a family
with three affected siblings [14]. Interestingly, Salzer et al
[12] had reported that of 13 affected individuals, nine had
inherited HLA*B8 and six had inherited HLA*B44. This
raised the possibility that joint inheritance of TACI muta-
tions and HLA-associated susceptibility haplotypes might
facilitate the development of immune deficiency and help
explain variations in penetrance. To test this hypothesis,
we examined TACI exons 3 and 4 among 63 patients with
CVID and among 13 patients with RESPI from our clinic
and tested for the joint presence of TACI and MHC-asso-
ciated susceptibility alleles.
Methods
Materials
We identified 63 CVID patients irrespective of HLA status
and 13 RESPI patients who had inherited HLA*B44. The
clinical and genetic features of these populations have
been previously described [6,11]. The study was per-
formed under the guidelines of the Institutional Review
Board of the University of Alabama at Birmingham.
Informed consent was obtained from all of the study par-
ticipants.
HLA typing
Human Leukocyte Antigen (HLA) -B and -DR alleles were
typed by PCR using LABType SSO PCR-SSO (Thermalcy-
cler; Luminex Corporation, Austin, TX) at low resolution.
Some patients were typed prior to the recognition of the
HLA -DR17 split product, causing us to refer to HLA -
DR17 as -DR3(17). We began to routinely perform HLA
haplotyping in 2000.
PCR amplification
We used the protocol of Castigli et al ([13]) to PCR
amplify and sequence TACI exons 3 and 4 from DNA iso-
lated from blood mononuclear cells.
Results
CVID
MHC haplotypes
Of the 63 patients with CVID, 23 out of 63 patients inher-
ited HLA B*44 (36.5%) and 21 out of 63 (33.3%) inher-
ited HLA*B8. Of these, 4 were compound HLA*B44 and
HLA*B8 heterozygotes (6.3%). Seventeen patients had
inherited at least one complete copy of the
HLA*B8,*DR17(3),*DQ2 haplotype (26.9%), and seven
had at least one complete copy of the HLA
B*44,*DR7,*DQ2 haplotype (11.1%). One patient had
inherited an entire copy of both of the haplotypes (UAB
00209). [Table 1]
TACI polymorphism
Seven of our patients were heterozygous for a silent T->G
polymorphism (P97P, rs35062843) in exon 3. The allele
frequency of 0.055 in this sample of patients was statisti-
cally indistinguishable from the frequency of 0.056
reported in dbSNP. Of these patients, 3 had inherited HLA
B*44 and one patient inherited HLA B*8. In exon 4, weBMC Medical Genetics 2009, 10:100 http://www.biomedcentral.com/1471-2350/10/100
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identified one patient (1.6%) who proved heterozygous
for the A181E mutation. This patient, who was from a
state adjoining Alabama, had inherited neither HLA *B44
or *B8. [Table 1]
The one patient who had inherited the TACI A181E allele
presented to our clinic when she was 35 years old. She
reported recurrent sinusitis, bronchitis, fatigue, and
malaise. A chest x-ray revealed bilateral pulmonary nod-
ules and mediastinal adenopathy. The physical examina-
tion revealed an enlarged spleen. The serum IgM was 28
mg/dl, the IgG was 256 gm/dl, and the IgA was reported
as < 8 mg/dl. Her absolute T count was 1,109 cells per
cmm with a CD4:CD8 ratio of 2.8. Her absolute B cell
count was 140 per cmm. She had only 67,000 platelets per
cmm of blood, and tests for anti-platelet antibodies were
positive. She was determined to be HLA *DQ4, DQ6; -
DR8, DR13, *B39, B62, and *A1, A3. She was placed on
immunoglobulin replacement therapy supplemented
with rotating prophylactic antibiotics. On 0.6 gm/kg of
IVIG, her trough IgG reached 840 mg/dl, the size of her
spleen markedly diminished, and the infections ceased.
She reported a marked improvement in her sense of well
being. Unfortunately, two years later she presented with a
recurrence of splenomegaly, fatigue, and malaise. She
underwent a splenectomy, but then proceeded to develop
hepatomegaly, portal hypertension, pulmonary effusions,
and ascites. A liver biopsy disclosed a polyclonal lym-
phocytic infiltrate. Lymphocytes were detected in the
pleural and ascitic fluid. Cultures were negative, but she
indicated symptomatic improvement after treatment with
broad spectrum antibiotics. She returned to the care of her
local physician who reported that her respite after antibi-
otic therapy did not last. She followed a progressive
downhill course and ultimately expired. An autopsy was
not performed.
RESPI
MHC Haplotypes
We selected thirteen consecutive RESPI patients who had
inherited HLA B*44 for study [Table 2]
TACI polymorphisms
In exon 3, we identified a silent T->G polymorphism
(P97P) in 4 of our patients (30.8%). In exon 4, we identi-
fied no mutations. [Table 2]
Discussion
Among patients with CVID, the frequent occurrence of
selective to generalized antibody deficiencies among first
or second degree relatives coupled with significant differ-
ences in prevalence among Americans of European versus
African descent have provided strong support for the view
that genetic inheritance plays an important role in the
development of the disease[6]. However, only a minority
of cases follow a simple Mendelian pattern of disease
transmission. Among these families, loss of function
mutations of key genes such as ICOS, CD19 and BAFF-R
Table 1: Characteristics of CVID patients with TACI exon 3 or 4 coding variants
HLA alleles
TACI allele Patient Sample Age at presentation B DR DQ Race/Gender IgM g/dl IgG g/dl IgA g/dl
P97P
UAB00067 35 8,51 17,13 2,6 W F 12 307 8
UAB00131 22 35,38 1,11 ND W M 5 312 1
UAB00256 49 38,51 4,11 3,3 W F 4 69 1
UAB00021 54 44,61 3,2 2,5 W M 34 339 17
UAB00245 35 44,44 7,15 2,6 W F 53 314 8
UAB00604 54 44,58 4,8 4,7 W F 27 525 55
UAB00111 32 ND ND ND W M 12 329 7
A181E
UAB00142 35 39,62 8,13 4,6 W F 33 279 8
Table 2: Characteristics of RESPI patients with P97P TACI coding variant
HLA alleles
TACI allele Patient Sample Age at presentation B DR DQ Race/Gender IgM g/dl IgG g/dl IgA g/dl
UAB00465 33 8,44 17,4 2,8 W F 151 1460 425
UAB00463 34 8,44 17,7 2,2 W F 133 757 221
UAB00183 37 44,27 11,15 6,7 W F 76 718 225
UAB00020 48 44,35 7,15 2,6 W F 153 754 105BMC Medical Genetics 2009, 10:100 http://www.biomedcentral.com/1471-2350/10/100
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have offered a clear mechanistic rationale for antibody
deficiency [2,3,5,15]. However, for the majority of
patients with CVID, it remains unclear whether the dis-
ease is sporadic, the product of an environmental insult,
the inheritance of a simple Mendelian trait with reduced
penetrance, or a combination of one or more genes inter-
acting with a chance environmental insult.
In 2005, replacement or frameshift mutations in the gene
for TACI were identified in 13 of 162 CVID cases by Salzer
et al [12] and in 4 of 19 cases by Castigli et al [13]. TACI
(TNFRSF13B) is a member of the tumor necrosis factor
receptor (TNFR) superfamily. It serves as a receptor for sol-
uble B cell activating factor of tumor necrosis factor family
(BAFF) and a proliferation inducing ligand (APRIL). These
TNF-like ligands play key roles in the maturation and sur-
vival of B cells in the periphery. Within this population of
patients, some of the probands carrying TACI polymor-
phisms demonstrated unique loss of function mutations.
However, others were heterozygous for one of two single
nucleotide polymorphisms (C104R and A181E), each of
which created a replacement mutation in either exons 3 or
4, respectively. These and other studies identified addi-
tional mutations (e.g. S144X, R202H, ins204A), all of
which were also found within exons 3 or 4 of TACI [16-
18]. These mutations appeared to engender susceptibility
to a form of selective or panhypogammaglobulinemia
that was transmitted as a Mendelian autosomal dominant
trait with incomplete penetrance [12,13].
Among the 13 patients reported by Salzer et al, nine had
inherited HLA*B8 and six had inherited HLA*B44, which
in our population are the two most prominent MHC alle-
les among our patients with CVID [12]. To us this raised
the possibility of epistasis between a mutant TACI allele
with altered function and an as yet unidentified gene or
genes located near the MHC class I locus.
To test for this possibility of synergy, we evaluated 63
CVID patients irrespective of MHC allele and 13 RESPI
patients who had inherited HLA *B44. Because multiple
studies had identified mutations predisposing to CVID
only within exons 3 and 4 [16-18], we focused our efforts
on this region of DNA. We found a replacement mutation
in TACI in only one patient. This provides support for the
hypothesis that "the overall pattern of HLA types in indi-
viduals with TACI deficiency seems to be different than in
individuals with idiopathic CVID" [12].
The CVID patient who was heterozygous for the A181E
polymorphism did not inherit either of the MHC alleles
that we have previously associated with IgAD or CVID in
our population. The clinical course followed by this
patient was more severe than what is common for our
population, which supports the view that the A181E
mutation places patients at a higher risk for complications
and thus may warrant closer monitoring and evaluation
[19].
The two original studies [12,13] reported a combined
total of 17 cases with TACI replacement or frameshift
mutations affecting exons 3 or 4 among 162 sporadic or
familial index cases with CVID (9.3%). A follow-up study
by Zhang et al [16] reported a frequency of 13 of 176
(7.3%) among sporadic cases alone. The frequency of 1 in
63 patients with a TACI mutation in exons 3 or 4 (1.6%)
in our patient population is lower than for these previous
studies (p = 0.056, χ2). It is possible that the inclusion of
familial cases biased ascertainment frequencies. The
majority of citizens of European descent in the state of
Alabama and its surrounding regions are the descendants
of a wave of immigrants from the states of Virginia, North
and South Carolina, and Georgia that occurred between
1815 and 1840. Most of these pioneers were the descend-
ants of peoples from Scotland, Ireland, Wales, and Eng-
land that had migrated to the southern coastal regions of
the United States in the previous century [20]. The low fre-
quency of the A181E and C104R polymorphisms in our
patient population may reflect genetic drift, founder
effects, or both.
Conclusion
In conclusion, our findings suggest that TACI mutations
are unlikely to play a critical role in creating susceptibility
to CVID among patients with previously recognized MHC
class I and class II susceptibility alleles. The one patient we
identified who inherited the TACI A181E allele had not
inherited either HLA *B44 or *B8.
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